<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02735473</url>
  </required_header>
  <id_info>
    <org_study_id>R01AA024123</org_study_id>
    <nct_id>NCT02735473</nct_id>
  </id_info>
  <brief_title>Choline Supplementation as a Neurodevelopmental Intervention in Fetal Alcohol Spectrum Disorders</brief_title>
  <official_title>Choline Supplementation as a Neurodevelopmental Intervention in Fetal Alcohol Spectrum Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota - Clinical and Translational Science Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Minnesota - Clinical and Translational Science Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled trial of choline supplementation in
      children with Fetal Alcohol Spectrum Disorders (FASD). The primary outcome measures are
      cognitive measures.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This project is the third in a series of randomized, double-blind placebo-controlled trials
      of choline bitartrate in children ages 2-5 who have been diagnosed with Fetal Alcohol
      Spectrum Disorders (FASD). Pre-clinical data suggests that choline may attenuate the
      cognitive deficits caused by prenatal alcohol exposure (especially memory deficits). This
      study will evaluate the effects of daily choline supplementation vs. placebo for 9 months.
      Outcome measures include an elicited imitation memory paradigm, global cognitive functioning,
      and aspects of executive functioning. The study will also continue to collect safety and
      tolerability data.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 2016</start_date>
  <completion_date type="Anticipated">May 2020</completion_date>
  <primary_completion_date type="Anticipated">May 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Elicited Imitation memory task - Short delay memory measure: 6 months</measure>
    <time_frame>Change from baseline to 6 months</time_frame>
    <description>Elicited Imitation memory paradigm - short delay memory measure at 6 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Elicited Imitation memory task - Short delay memory measure: 9 months</measure>
    <time_frame>Change from baseline to 9 months</time_frame>
    <description>Elicited Imitation memory paradigm - short delay memory measure at 9 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Stanford-Binet Intelligence Scales: 9 months</measure>
    <time_frame>Change from baseline to 9 months</time_frame>
    <description>Stanford-Binet Intelligence Scales at 9 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minnesota Executive Function Scale: 6 months</measure>
    <time_frame>Change from baseline to 6 months</time_frame>
    <description>Minnesota Executive Function Scale - Early Childhood Version at 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minnesota Executive Function Scale: 9 months</measure>
    <time_frame>Change from baseline to 9 months</time_frame>
    <description>Minnesota Executive Function Scale - Early Childhood Version at 9 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NIH Toolbox Flanker Task: 6 months</measure>
    <time_frame>Change from baseline to 6 months</time_frame>
    <description>NIH Toolbox Flanker Inhibitory and Control Task at 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NIH Toolbox Flanker Task: 9 months</measure>
    <time_frame>Change from baseline to 9 months</time_frame>
    <description>NIH Toolbox Flanker Inhibitory and Control Task at 9 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Child Behavior Checklist: 6 months</measure>
    <time_frame>Change from baseline to 6 months</time_frame>
    <description>Child Behavior Checklist - parent report instrument at 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Child Behavior Checklist: 9 months</measure>
    <time_frame>Change from baseline to 9 months</time_frame>
    <description>Child Behavior Checklist - parent report instrument at 9 months</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Fetal Alcohol Spectrum Disorders</condition>
  <arm_group>
    <arm_group_label>Choline bitartrate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Powdered drink mix containing choline bitartrate 19 mg. per kg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Powdered drink mix containing matching placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Choline bitartrate</intervention_name>
    <arm_group_label>Choline bitartrate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Ages 2 years to 5 years of age

          2. Available parent or legal guardian capable of giving informed consent for
             participation.

          3. Documented prenatal alcohol exposure (self-report, social service records, or adoption
             records).

          4. Modified Institute of Medicine (IOM) criteria for Fetal Alcohol Syndrome (FAS),
             Partial Fetal Alcohol Syndrome (PFAS), or Alcohol-Related Neurodevelopmental Disorder
             (ARND) (Hoyme, May, et al., 2005).

        Exclusion Criteria:

          1. Known history of a neurological condition (ex. epilepsy, traumatic brain injury)

          2. Known history of a medical condition known to affect brain function.

          3. Known history of other neurodevelopmental disorder (ex. autism, Down syndrome)

          4. Known history of very low birthweight (&lt;1500 grams)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>5 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey R Wozniak, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota - Clinical and Translational Science Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jeffrey R Wozniak, Ph.D.</last_name>
    <phone>612-273-9741</phone>
    <email>jwozniak@umn.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michael K Georgieff, M.D.</last_name>
    <phone>612-626-2971</phone>
    <email>georg001@umn.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55454</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Birgit Fink</last_name>
      <phone>612-624-0142</phone>
      <email>fasd@umn.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jeff Wozniak, Ph.D.</last_name>
      <phone>612-273-9741</phone>
      <phone_ext>Wozniak</phone_ext>
      <email>jwozniak@umn.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Jeffrey R Wozniak, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Georgieff, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 2, 2016</study_first_submitted>
  <study_first_submitted_qc>April 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 12, 2016</study_first_posted>
  <last_update_submitted>April 30, 2018</last_update_submitted>
  <last_update_submitted_qc>April 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Fetal Alcohol Spectrum Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Choline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

